Moat ranks
Balance sheet
| £B | Dec 31 | Jun 30 |
|---|---|---|
| Cash | 3.4 | 1.9 |
| Securities | 0.0 | 0.0 |
| Restricted cash | 0.3 | 0.5 |
| Debt | 34.5 | 34.6 |
| Net cash | -31.1 | -32.6 |
| Equity | 46.0 | 46.5 |
- Debt / EBITDA · 12/31/25
- 2.82×
- Debt / equity
- 0.74×
- Leases (6/30/26)
- £513M
- Diluted shares
- 2,176M
- Book value / share
- £21.36
- Price / book
- 2.1×
- Net cash / share
- −£14.99
- Market cap
- £97.9B
- Enterprise value
- £130.5B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | 1.4% | +3.6 pts | |
| Operating margin | 34.9% | -7.1 pts | |
| FCF margin | 26.4% | +8.5 pts | |
| Capex / revenue | 1.4% | +0.2 pts | |
| Cigarette shipments | 218.00B | -5% | |
| Combustibles price/mix | 6.8% | – | |
| Vapour consumables | 263.0M | +4% | |
| Heated-product consumables | 8.90B | -12% | |
| Heated-product share movement | -1 | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About BATS
BAT sells cigarettes, Vuse vapour products, glo heated products, Velo nicotine pouches and traditional oral tobacco. Cigarettes supplied 78.9% of 2025 revenue.
- Brand Trust
Newport, Camel, Natural American Spirit and international cigarette brands support recurring premium sales in markets where advertising restrictions make it hard to build a new brand.
- Installed Base Consumables
Vuse reusable devices work with compatible pods, and BAT reported 12.7m adult vapour consumers at the end of 2025.
- Compliance Advantage
FDA authorization permits sale of specific Vuse Alto tobacco-flavoured pods and the accompanying device.
- Brand Trust
Vuse’s U.S. tracked retail value share rose from 51.7% in 2025 to 55.9% in H1 2026 and 56.8% at/YTD August.
- Oct 28, 2026
BAT announced Bruce Sewell as an independent director effective January 1, 2027 and committee changes effective November 30, 2026. The latest financial statements remain the June half-year, with September Capital Markets Day providing the current outlook.
- Oct 1, 2026
The UK introduced GBP2.20 vape duty per 10ml and raised tobacco duty, increasing consumer prices or reducing manufacturer margins; mandatory vape duty stamps follow in April 2027.
- Sep 29, 2026
BAT presented Horizon 2030, targeting mid-teens New Category revenue growth and at least 30% contribution margin by 2030. It retained its FY2026 revenue/profit guidance and expected a 2-2.5% EPS currency headwind.
- Sep 1, 2026
Dragos Constantinescu became BAT’s CFO and executive director, replacing the interim finance arrangement as the group works to fund smokeless growth and reduce debt.
- Aug 21, 2026
FDA authorized 11 rival ZYN ULTRA products for PMI, expanding higher-strength pouch competition against Velo and Grizzly.
Ownership
Go deeper on BATS
- Compare stock research toolsFundamentals, valuation and screening platforms for BATS.19 tools
- See BATS's price chartNo price chart here yet. See price history and indicators.17 tools
- Read BATS's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (£) | |||||||||||||
| Revenue | 7.58 | 9.54 | 10.69 | 11.30 | 11.23 | 11.18 | 12.20 | 12.24 | 11.63 | 11.65 | 11.85 | +4.9%/yr | |
| Cash flow | 2.47 | 2.61 | 4.49 | 3.93 | 4.26 | 4.23 | 4.58 | 4.81 | 4.55 | 2.88 | 3.42 | +1.7%/yr | |
| Earnings | 2.49 | 18.28 | 2.63 | 2.49 | 2.79 | 2.96 | 2.94 | -6.45 | 1.38 | 3.53 | 2.96 | +3.9%/yr | |
| Free cash flow | 2.11 | 2.13 | 4.08 | 3.57 | 3.94 | 3.91 | 4.30 | 4.54 | 4.28 | 2.56 | 3.08 | +2.2%/yr | |
| Capex | 0.36 | 0.48 | 0.41 | 0.36 | 0.33 | 0.32 | 0.29 | 0.27 | 0.27 | 0.32 | 0.33 | -1.3%/yr | |
| Dividends | 1.56 | 1.69 | 1.90 | 2.01 | 2.07 | 2.13 | 2.17 | 2.27 | 2.34 | 2.38 | 2.42 | +4.8%/yr | |
| Book value | 4.39 | 29.65 | 28.55 | 27.89 | 27.31 | 28.48 | 32.50 | 22.83 | 21.55 | 20.93 | 21.36 | +19.0%/yr | |
| Diluted shares (M) | 1,865 | 2,051 | 2,292 | 2,291 | 2,295 | 2,297 | 2,267 | 2,229 | 2,225 | 2,199 | 2,176 | +1.8%/yr | |
| Totals (£B) | |||||||||||||
| Revenue | 14.1 | 19.6 | 24.5 | 25.9 | 25.8 | 25.7 | 27.7 | 27.3 | 25.9 | 25.6 | 25.8 | +6.8%/yr | |
| Operating income | 4.7 | 6.4 | 9.3 | 9.0 | 10.0 | 10.2 | 10.5 | -15.8 | 2.7 | 10.0 | 9.2 | +8.9%/yr | |
| Net income | 4.6 | 37.5 | 6.0 | 5.7 | 6.4 | 6.8 | 6.7 | -14.4 | 3.1 | 7.8 | 6.4 | +5.9%/yr | |
| Free cash flow | 3.9 | 4.4 | 9.4 | 8.2 | 9.0 | 9.0 | 9.7 | 10.1 | 9.5 | 5.6 | 6.7 | +4.1%/yr | |
| Buybacks | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | 2.1 | 0.1 | 0.8 | 1.2 | 1.4 | +38.1%/yr | |
| Dividends | 2.9 | 3.5 | 4.3 | 4.6 | 4.7 | 4.9 | 4.9 | 5.1 | 5.2 | 5.2 | 5.3 | +6.7%/yr | |
| Net cash | -17.4 | -46.3 | -45.0 | -43.0 | -41.8 | -37.9 | -41.0 | -37.0 | -33.6 | -31.1 | -32.6 | −£13.7B | |
| Margins & returns (%) | |||||||||||||
| Operating margin | 32.9 | 32.8 | 38.0 | 34.8 | 38.6 | 39.8 | 38.1 | -57.7 | 10.6 | 39.0 | 35.7 | +6.1 pts | |
| Net margin | 32.9 | 191.6 | 24.6 | 22.0 | 24.8 | 26.5 | 24.1 | -52.7 | 11.9 | 30.3 | 25.0 | -2.6 pts | |
| FCF margin | 27.9 | 22.3 | 38.2 | 31.6 | 35.0 | 34.9 | 35.2 | 37.1 | 36.8 | 22.0 | 26.0 | -5.8 pts | |
| ROIC | 13.6 | 4.5 | 6.3 | 6.3 | 7.2 | 7.4 | 6.9 | -13.4 | 2.5 | 9.7 | 8.7 | -3.9 pts | |
| Return on equity | 56.8 | 61.6 | 9.2 | 8.9 | 10.2 | 10.4 | 9.0 | -28.2 | 6.4 | 16.9 | 13.9 | -39.9 pts | |
| R&D % of revenue | 1.0 | 1.0 | 1.1 | 1.5 | 1.2 | 1.2 | 1.2 | 1.5 | 1.5 | 1.4 | 1.4 | +0.4 pts | |
| Stock pay % of revenue | 0.6 | 0.6 | 0.5 | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | – | -0.2 pts | |
| Capex % of revenue | 4.8 | 5.0 | 3.9 | 3.1 | 2.9 | 2.9 | 2.4 | 2.2 | 2.4 | 2.7 | 2.8 | -2.0 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- medium
- Trajectory
- narrowing
- Pricing power
- strong
- Combustibles78.9%1 claim
- Vapour6.0%3 claims
- Heated Products3.6%1 claim
- Modern Oral4.5%1 claim
- Traditional Oral4.1%1 claim
- Other2.9%Not scored: evidence insufficient
Moat claims
- Applies to
- Combustibles
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Jul 30, 2026
Newport, Camel, Natural American Spirit and international cigarette brands support recurring premium sales in markets where advertising restrictions make it hard to build a new brand. H1 2026 price/mix of +6.8% helped keep combustibles revenue growing at constant currency, but cigarette value share fell 40 basis points in BAT’s priority markets. Nicotine dependence sustains category demand; it is not exclusive to BAT.
H1 2026 cigarette value share fell 40 basis points and shipments fell 4.6%; pricing still supports profit, but BAT is losing part of the shrinking customer pool.
- Cigarette shipments218.00B-5%
- Combustibles price/mix6.8%
- Plain packaging and marketing restrictions reduce brand differentiation
- Accelerating volume declines from health trends and regulation
- Downtrading to deep-discount brands (and illicit trade)
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- Applies to
- Vapour
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jul 30, 2026
Vuse reusable devices work with compatible pods, and BAT reported 12.7m adult vapour consumers at the end of 2025. H1 2026 consumables volume returned to growth, but the total includes disposable formats and does not reveal reusable-device retention. Low device prices and illicit flavoured products keep switching easy.
H1 2026 vapour consumables rose 4.2% to 263m units, following a 12.6% fall in 2025; recovery helps the installed base, but repeat purchases and churn are not separately disclosed.
- Vapour consumables263,000,000+4%
- Vapour consumers12,700,000+7%
- New Category contribution£257M+55%
- Smokeless consumers35,000,000
- Consumers switch to subsidized rival devices or illicit disposables
- Flavor restrictions reduce compatible consumable choice
- Open systems and standardized formats reduce platform friction
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- Applies to
- Vapour
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 6, 2026
FDA authorization permits sale of specific Vuse Alto tobacco-flavoured pods and the accompanying device. The scientific submission burden helps BAT in compliant channels, but authorization is product-specific and does not cover every Vuse flavour. May 2026 enforcement priorities give some unauthorized products lower enforcement priority; that is different from approval.
Vuse retains its seven-product Alto tobacco authorization while the May 2026 policy changes enforcement priorities; legal access remains valuable, but it is not exclusive and enforcement still limits the benefit.
- U.S. vapour value share56.8%
- New Category contribution£257M+55%
- Adverse regulation (flavor restrictions, product bans)
- PMTA denials or litigation outcomes limiting product line
- Policy shifts that weaken enforcement against illicit products
- SourceFDA authorization of Vuse Alto tobacco-flavoured pods and power unitJul 18, 2024
- SourceFDA May 2026 enforcement priorities for new tobacco products without premarket authorizationMay 8, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- Applies to
- Vapour
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Sep 29, 2026
Vuse’s U.S. tracked retail value share rose from 51.7% in 2025 to 55.9% in H1 2026 and 56.8% at/YTD August. That shows stronger shelf performance in these channels. H1 share losses in Europe and Canada, and large untracked illicit sales, prevent a claim that Vuse dominates all consumer demand.
U.S. tracked retail value share reached 56.8% at/YTD August 2026, versus 51.7% in 2025; stronger shelf demand supports the brand, though Europe and Canada remain weaker.
- Vapour consumables263,000,000+4%
- U.S. vapour value share56.8%
- New Category contribution£257M+55%
- Smokeless consumers35,000,000
- Brand equity erodes if illegal products dominate consumer preference
- Product quality/safety issues harm trust
- Rapid innovation cycles narrow differentiation
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- SourceBAT Capital Markets Day 2026, Horizon 2030, YTD August U.S. retail sharesSep 29, 2026
- Applies to
- Heated Products
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Jul 30, 2026
Glo devices heat specially designed tobacco or herbal consumables, creating a recurring-sales platform. The mechanism is real but contested: H1 2026 sticks fell 12.2% to 8.9bn and priority-market volume share fell another 1.2 percentage points. IQOS and Ploom offer competing ecosystems, while cheap or subsidized devices make migration affordable.
H1 2026 heated-product consumables fell 12.2% to 8.9bn and priority-market share fell 1.2 percentage points, showing that glo is losing recurring demand despite new-device launches.
- Heated-product consumables8.90B-12%
- Heated-product share movement-1
- New Category contribution£257M+55%
- Smokeless consumers35,000,000
- IQOS and local platforms dominate device and consumable availability
- Devices are subsidized, making consumer switching inexpensive
- Regulation or tax treatment reduces heated-product adoption
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- Applies to
- Modern Oral
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Sep 29, 2026
Velo and Grizzly pouches are gaining consumers in the U.S. and BAT remains a category leader in its established European markets. Top-market volume share reached 39.2% in H1 2026 and U.S. share reached 30.5% at/YTD August. The gains are stronger evidence than a brand-building plan, but affordable switching and ZYN’s broader authorizations keep the advantage contested.
H1 2026 Top-market volume share reached 39.2% and pouch shipments grew 57.5%; U.S. tracked share then reached 30.5% at/YTD August, showing that Velo’s gains extend beyond category growth.
- Modern oral pouches7.90B+57%
- Modern oral volume share39.2%
- U.S. modern oral volume share30.5%
- New Category contribution£257M+55%
- Smokeless consumers35,000,000
- Dominant competitors with stronger scale/brand in pouches
- Flavor or nicotine strength restrictions
- Price competition and promotions to win share
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
- SourceBAT Capital Markets Day 2026, Horizon 2030, YTD August U.S. retail sharesSep 29, 2026
- SourcePMI: FDA authorizes 11 ZYN ULTRA productsAug 21, 2026
- Applies to
- Traditional Oral
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Jul 30, 2026
Grizzly and Kodiak have established positions in U.S. moist snuff, which supports repeated purchases and some pricing room. H1 2026 U.S. price/mix was +7.2%. The advantage is modest because users are moving to pouches, BAT loses share and rival Copenhagen and Skoal brands have their own established franchises.
H1 2026 U.S. traditional oral volume fell 12.4% and value share fell 40 basis points; pricing cannot fully offset consumers switching to pouches.
- Smokeless consumers35,000,000
- Traditional oral consumables2.50B-10%
- U.S. traditional oral price/mix7.2%
- Pouches replace moist snuff and snus for some existing users.
- High prices encourage trading down to cheaper snuff brands.
- Marketing, flavours and tobacco taxation can restrict brand differentiation.
- FilingBAT Annual Report 2025, financial statements and product-category reviewFeb 13, 2026
- FilingBAT Half-Year Report, six months to 30 June 2026Jul 30, 2026
Profile change log
- Nov 11, 2026 · business change
BAT announced Bruce Sewell as an independent director effective January 1, 2027 and committee changes effective November 30, 2026. The latest financial statements remain the June half-year, with September Capital Markets Day providing the current outlook.
- Oct 6, 2026 · analyst revision
The investment debate now tests whether smokeless cash can cover cigarette decline and recurring Canadian payments. Shared market profiles explain industry leaders, product switching, taxes, currency, input costs and interest-rate exposure.
- Oct 6, 2026 · method change
Category contribution leaves out central costs, so category operating-profit shares have been removed. Glo’s implied 15.2% share is no longer presented as a current absolute observation; the directly reported 2024 share and later reported declines remain available. Earlier priority-market baskets are not joined into one share series.
- Oct 6, 2026 · analyst revision
Grizzly and Kodiak’s repeated pricing evidence supports a modest traditional-oral brand advantage, with consumer migration to pouches narrowing it. Other remains unscored because its leaf, distribution and adjacent activities lack enough common competitive evidence.
- Oct 6, 2026 · analyst revision
The latest shipment and share evidence points to narrowing cigarette and glo advantages, a stable Vuse device/compliance advantage, and widening Velo and U.S. Vuse brand demand. The profiles now distinguish tracked-channel share from all consumer demand.
- Oct 6, 2026 · business change
The UK introduced GBP2.20 vape duty per 10ml and raised tobacco duty, increasing consumer prices or reducing manufacturer margins; mandatory vape duty stamps follow in April 2027.
- Oct 6, 2026 · business change
BAT presented Horizon 2030, targeting mid-teens New Category revenue growth and at least 30% contribution margin by 2030. It retained its FY2026 revenue/profit guidance and expected a 2-2.5% EPS currency headwind.
- Oct 6, 2026 · business change
Dragos Constantinescu became BAT’s CFO and executive director, replacing the interim finance arrangement as the group works to fund smokeless growth and reduce debt.
- Oct 6, 2026 · business change
FDA authorized 11 rival ZYN ULTRA products for PMI, expanding higher-strength pouch competition against Velo and Grizzly.
- Oct 6, 2026 · business change
BAT announced a future marketing and APMEA leadership change: Pascale Meulemeester will become marketing chief on March 1, 2027 and Celina Li joins as APMEA director designate, changing who leads the product transition.
- Oct 6, 2026 · business change
FDA changed enforcement priorities for some nicotine products without marketing authorization; this may widen product access but does not give every Vuse or Velo product approval.
- Oct 6, 2026 · business change
BAT implemented the Canadian tobacco settlement, resolving historical claims while committing accumulated cash and a share of future Canadian earnings to claimants.
- Oct 6, 2026 · business change
FDA authorized seven Vuse Alto tobacco-flavoured products and the associated power unit, strengthening access to compliant U.S. retail channels.
- Oct 6, 2026 · business change
BAT completed the Russia and Belarus sale, removing those businesses from later group revenue and recognizing a disposal charge.
- Oct 6, 2026 · business change
BAT bought the remaining Reynolds American shares, consolidating the U.S. business and replacing associate earnings with product sales; debt and acquired brands became much larger parts of its balance sheet.
- Oct 6, 2026 · business change
BAT issued two USD750m fixed-rate notes, at 5.300% to 2033 and 5.550% to 2036, for general corporate purposes including possible debt repayment. The deal extends funding while committing future interest cash.
- Oct 6, 2026 · business change
BAT completed a second ITC block trade of 313m shares for approximately GBP1.05bn net proceeds, increasing funding for the smokeless transition, debt reduction and share purchases.
- Oct 6, 2026 · business change
Ontario’s court sanctioned the Canadian tobacco settlement plans, clearing the legal path to resolve historical claims through upfront and future earnings-based payments.
- Oct 6, 2026 · business change
ITC demerged its hotels business. BAT received a direct ITC Hotels stake and recognized a post-tax gain, expanding its separate investment portfolio.
- Oct 6, 2026 · business change
BAT completed an ITC block trade of 436,851,457 shares, releasing cash for debt reduction and capital returns while reducing future associate earnings.
- Oct 6, 2026 · business change
Reynolds completed the sale of Natural American Spirit rights outside the U.S. to Japan Tobacco. BAT’s associate gain increased 2016 earnings without recurring product profit.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Major legal combustible tobacco markets
Legal cigarettes and other combustible tobacco products in the international markets outside China covered by BAT’s industry outlook. The size figure is manufacturer/category revenue in that model, not tax-inclusive retail spending or a complete global census; smokeless nicotine products are excluded.
- Philip Morris International
- British American Tobacco
- Japan Tobacco
- Imperial Brands
- Altria
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| BATS | 69 | – | 35.7% | |
| Industry median | 3 | 88 | – | – |
| Sector median | 85 | 74 | 55.3% | 17.0% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Established brands and limited advertising access make it harder for new manufacturers to win recurring adult smokers.
- Price increases and a shift between premium and value packs can support nominal manufacturer revenue despite declining cigarette volume.
- Smokers moving to pouches, heated tobacco and vapour change the nicotine profit pool; manufacturers with successful alternatives can retain part of that spending.
- Currency translation can materially change reported profit without changing local demand. PMI raised September 2026 EPS guidance by USD0.09 for currency only, while BAT expected a 2–2.5% currency headwind; exposure depends on each issuer’s reporting currency and sales mix.
- Habitual consumption makes volumes less sensitive to ordinary recessions than durable goods, but tighter household budgets change the brand and legal/illicit mix.
- High excise taxes, plain packaging, menthol/flavour restrictions and birth-cohort sales bans can weaken branded legal sales. The UK cohort restriction starts January 1, 2027.
- Discount brands and illicit cigarettes can take demand when legal prices rise faster than income. BAT estimated about 80% illicit volume in Australia in H1 2026; that is a company estimate for one country, not a global share.
- Healthcare and product-liability claims can take large cash sums. BAT’s Canadian settlement resolved historical litigation but commits a portion of future Canadian earnings.
- Poor leaf harvests and higher packaging, energy and freight costs can compress returns if manufacturers cannot pass them on without losing consumers.
- Refinancing is a slower risk than daily interest changes for fixed/hedged debt. BAT’s 2025 modeled pretax loss from a 100-basis-point rate increase was GBP27m; maturities and currency mismatches still matter.
Bulls & bears
Can Velo and Vuse generate enough recurring cash to offset cigarette decline, Canadian settlement payments and the cost of building the smokeless business?
Arguments
What to watch
- 1Cigarette volume, value share and price/mix excluding excise-duty effects
- 2Velo pouch volume and U.S. share; Vuse consumables and tracked share
- 3Current-currency New Category contribution, capex and operating cash flow
- 4Canadian settlement payments and cash available after interest and shareholder distributions
Next check: The FY2026 results: test the September guidance against actual cash, New Category contribution and U.S. share; also check the UK vape-duty rollout and April 1, 2027 duty-stamp deadline.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 69/100 by <a href="https://www.findmymoat.com/stocks/XLON:BATS">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.